All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Professor Nathan Fowler is a Professor of Medicine at The University of Texas MD Anderson Cancer Center, Houston, US. Prof. Fowler completed his medical degree at The University of Texas Medical Branch at Galveston, Galveston, US, in 2001, following a BS in Biology at the University of Houston, Houston, US. He then undertook further postgraduate training at The University of Texas Medical Branch before becoming a Clinical Fellow at Georgetown University, Washington, US, in 2004 and Chief Fellow in 2006. In 2007, he took up an Assistant Professor position at the MD Anderson Cancer Center, before arriving at his current post.
Having helped develop some of the first protocols to use lenalidomide in chronic lymphocytic leukemia, the goal of his clinical research at the MD Anderson Cancer Center has been to further develop novel therapeutic regimens utilizing immunomodulatory agents to benefit patients with low grade non-Hodgkin lymphoma. He also serves as the chairman for many phase I and II trials for patients with non-Hodgkin lymphoma, including the largest clinical study to use immunomodulatory drugs for untreated low-grade lymphoma.
Positions of responsibility/awards: